Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
002589.SZ
HOLDGet insider-trade alertsRealcan Pharmaceutical Group Co., Ltd. · Healthcare · China · $543M · Avg Vol: $11M/d
39
StockRankQ
46
V
52
M
34
P/E (TTM)
245.0x
ROE
0.8%
D/E
0.9x
Dividend %
0.1%
COMPANY DESCRIPTION
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.8B | 1.2B | 1.2B | 1.1B | -16.0% | 1.1B |
| EPS | -0.18 | 0.00 | 0.00 | 0.00 | -13.9% | 0.00 |
| Shares | 1.5B | 1.5B | 1.5B | 1.5B | 0.0% | 1.5B |
| Debt | 577.1M | 1.0B | 969.7M | 678.2M | 5.5% | 742.2M |
| Equity | 796.4M | 802.4M | 817.2M | 780.5M | -0.7% | — |
| Op CF | 77.0M | 12.1M | 23.7M | 2.0M | -70.3% | -4.0M |
| Inv CF | 87.3M | 85.4M | 30.0M | -7.6M | — | — |
| Fin CF | -215.8M | -99.7M | -21.6M | 9.7M | — | — |
Loading 1Y...
PRICE (1Y)-9.6%
SMA 50SMA 200
Close
$0.3903
RSI (14)
46.0
52W High
$0.6902
From 52W High
0.6%
SCORE BREAKDOWN
Quality
46
ROIC
3.2%51.0
ROE
0.8%46.1
GP/Assets
5.2%19.1
Op. Margin
3.7%52.1
FCF/Assets
16.1%94.0
Piotroski
667.4
Int. Cover
1.0x38.6
D/E Ratio
0.93x17.1
Current Ratio
1.10x13.9
Value
52
P/E (TTM)
245.0x4.0
EV/EBITDA
18.0x34.0
P/FCF
1.6x98.6
P/B
0.7x91.7
P/S
0.5x91.9
Div Yield
0.1%0.6
Momentum
34
52W High %
57%29.8
RS 6M
-28%36.9
SMA 50/200
0.92x43.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-14%28.0
FUNDAMENTALS
Market Cap
$543M
P/E (Forward)
—
Gross Margin
10.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 002589.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 002589.SZ | Realcan Pharmaceutical Group Co., Ltd.(you) | $543M | 39 | HOLD |
| 301584.SZ | Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. | $1.2B | 29 | SELL |
| 000950.SZ | C.Q. Pharmaceutical Holding Co., Ltd. | $1.3B | 51 | HOLD |
| 2656.HK | 160 Health International Limited | $419M | 5 | STRONG SELL |
| AHG | Akso Health Group | $1.3B | 12 | STRONG SELL |
| 600739.SS | Liaoning Cheng Da Co., Ltd. | $2.2B | 56 | HOLD |
| 0314.HK | Sipai Health Technology Co., Ltd. | $119M | 18 | STRONG SELL |
| 1931.HK | ETHK Labs Inc. | $125M | 14 | STRONG SELL |
| 603368.SS | Guangxi LiuYao Group Co., Ltd | $854M | 92 | STRONG BUY |
| 600056.SS | China Meheco Group Co., Ltd. | $1.9B | 80 | BUY |
Peer medians: ROE 4.8% · P/E 26.5x · Gross margin 52.5%